Tempest Therapeutics Inc (TPST) gains 0.17% for July 21

Equities Staff  |

Tempest Therapeutics Inc (NASDAQ: TPST) shares gained 0.17%, or $0.03 per share, to close Wednesday at $17.93. After opening the day at $17.00, shares of Tempest fluctuated between $18.32 and $16.75. 242,812 shares traded hands a decrease from their 30 day average of 1,799,564. Wednesday's activity brought Tempest’s market cap to $341,441,600.

Tempest is headquartered in Ann Arbor, Michigan..

About Tempest Therapeutics Inc

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.

Visit Tempest Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Tempest Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Tempest Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content